PYPD

Polypid Ltd

5.78

Oct 28 • 3:59 PM ET +0.01 (0.17%)

5.85

Aftermarket • 7:30 PM ET +0.07 (1.23%)

Healthcare Biotechnology Israel Micro NASD

Today, 8:36 AMPolyPid unveils PD01B Kynatrix-based controlled-release doxycycline candidate for moderate to severe diabetic foot infections, targets new NDA in 2027

Peers: CRMD HRTX EPRX CTXR SPRO INVA PCRX VANI OCUL ACXP

Scroll to Statements

Index	-
Market Cap	117.40M
Enterprise Value	112.20M
Income	-31.50M
Sales	0.00M
Book/sh	0.27
Cash/sh	0.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	75
IPO	Jun 26, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	21.79
P/C	17.34
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.14
Current Ratio	1.35
Debt/Eq	0.29
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-1.48
EPS next Y	-1.05
EPS next Q	0.93
EPS this Y	95.02%
EPS next Y	-905.23%
EPS next 5Y	41.71%
EPS past 3/5Y	-0.87% 14.14%
Sales past 3/5Y	- -
EPS Y/Y TTM	61.30%
Sales Y/Y TTM	-
EPS Q/Q	55.37%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	7.28% -

Insider Own	63.91%
Insider Trans	0.00%
Inst Own	17.10%
Inst Trans	5.49%
ROA	-119.05%
ROE	-243.59%
ROIC	-555.57%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.80%
SMA50	11.75%
SMA200	22.57%
Trades

Shs Outstand	20.31M
Shs Float	7.33M
Short Float	3.08%
Short Ratio	1.81
Short Interest	0.23M
52W High	5.79 -0.17%
52W Low	3.50 65.14%
Volatility	5.02% 5.29%
ATR (14)	0.27
RSI (14)	68.16
Beta	1.45
Rel Volume	1.09
Avg Volume	124.29K
Volume	135,038

Perf Week	14.00%
Perf Month	9.26%
Perf Quarter	32.27%
Perf Half Y	27.59%
Perf YTD	33.18%
Perf Year	55.80%
Perf 3Y	52.91%
Perf 5Y	-97.27%
Perf 10Y	-
Recom	1.00
Target Price	11.40
Prev Close	5.77
Price	5.78
Change %	0.17%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-26	Initiated	Oppenheimer	Outperform	$10
Jun-05-25	Initiated	Roth Capital	Buy	$9
Jun-02-25	Resumed	H.C. Wainwright	Buy	$11
Jan-28-25	Initiated	Rodman & Renshaw	Buy	$13
Sep-14-21	Initiated	JMP Securities	Mkt Outperform	$14
Jul-30-21	Initiated	Cantor Fitzgerald	Overweight	$24
Nov-24-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-10-20	Initiated	Alliance Global Partners	Buy	$27
Jul-21-20	Initiated	Raymond James	Outperform	$23
Jul-21-20	Initiated	BMO Capital Markets	Outperform	$30
Jul-21-20	Initiated	Barclays	Overweight	$22

Show Previous Ratings

Today 08:00AM	PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix Based Product Candidate for the Treatment of Diabetic Foot Infections (GlobeNewswire)
Oct-21-26 08:00AM	PolyPid to Present D-PLEX100 Microbiology Data at IDWeek 2026 (GlobeNewswire)
Oct-15-26 08:30AM	PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 (GlobeNewswire)
Oct-09-26 08:00AM	What PolyPid's Bold Moves in Europe Could Mean for D-PLEX100's Global Potential (NASDAQ: PYPD) (FinanceWire)
Oct-01-26 09:15AM	European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX100 (GlobeNewswire)
08:56AM	Loading…
08:56AM	PolyPid Regains European Commercialization Rights for D-PLEX100, Expanding Global Commercialization Opportunities (GlobeNewswire)
Sep-15-26 08:30AM	PolyPid Announces Participation in Upcoming Fall Investor Conferences (GlobeNewswire)
Aug-12-26 07:03PM	PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... (GuruFocus.com)
07:30AM	PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-31-26 11:28AM	PolyPid's Double Win: D-PLEX100 Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD) (FinanceWire)
Jul-30-26 08:00AM	PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 (GlobeNewswire) +7.11%
Jul-29-26 08:30AM	PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100 (GlobeNewswire) +8.80%
Jul-21-26 08:49AM	PolyPid Locks in a Transformative Deal Worth Over $320 Million, With Additional Major Royalty Potential (FinanceWire) -27.38%
07:30AM	PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX100 in the U.S. and Canada (GlobeNewswire)
Jul-14-26 08:30AM	Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That (FinanceWire) +6.15%
03:05PM	Loading…
Jun-25-26 03:05PM	Lilly's $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid's Asset is Hiding in Plain Sight (FinanceWire)
Jun-01-26 08:30AM	PolyPid Completes New Drug Application Submission to FDA for D-PLEX100 (GlobeNewswire) +7.42%
May-20-26 08:30AM	PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference (GlobeNewswire)
May-13-26 07:01PM	PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -7.46%
07:30AM	PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 08:00AM	PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 (GlobeNewswire)
Apr-28-26 08:30AM	PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting (GlobeNewswire)
Apr-13-26 09:15AM	PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX100 Sustained Local Release at ESCMID Global 2026 (GlobeNewswire)
Mar-31-26 08:30AM	PolyPid Initiates D-PLEX100 NDA Submission to the FDA (GlobeNewswire)
Mar-17-26 08:30AM	PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX100's New Drug Application (GlobeNewswire)
Feb-25-26 08:35AM	PolyPid Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Feb-11-26 04:03PM	PolyPid Ltd (PYPD) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com)
09:52AM	PolyPid Q4 Earnings Call Highlights (MarketBeat)
07:30AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Jan-28-26 08:00AM	PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 (GlobeNewswire)
08:30AM	Loading…
Dec-16-25 08:30AM	PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors (GlobeNewswire)
Dec-03-25 08:30AM	PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission (GlobeNewswire)
Nov-25-25 08:30AM	PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 (GlobeNewswire)
Nov-12-25 04:01PM	PolyPid Ltd (PYPD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges (GuruFocus.com)
07:30AM	PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-06-25 08:30AM	PolyPid's D-PLEX100 Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year" (GlobeNewswire)
Oct-29-25 08:30AM	PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025 (GlobeNewswire)
Sep-30-25 08:45AM	PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress (GlobeNewswire)
Sep-17-25 08:44AM	PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-16-25 08:30AM	PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX100 (GlobeNewswire)
Sep-03-25 08:30AM	PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Sep-02-25 08:30AM	PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference (GlobeNewswire)
Aug-14-25 03:08AM	PolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Aug-13-25 07:30AM	PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-12-25 08:00AM	PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer (GlobeNewswire) +5.88%
Jul-30-25 08:00AM	PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025 (GlobeNewswire)
Jul-15-25 10:00AM	Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech (GlobeNewswire)
08:00AM	PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market (GlobeNewswire)
Jun-22-25 06:15AM	Analysts Predict Up to ~590% Spike for These 2 Strong Buy Penny Stocks (TipRanks)
Jun-16-25 07:20PM	PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results (GlobeNewswire) +7.62%
Jun-09-25 12:53PM	Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial (Benzinga)
07:30AM	PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints (GlobeNewswire)
Jun-06-25 04:05PM	PolyPid to Host Conference Call and Webcast to Discuss D-PLEX100 SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 (GlobeNewswire)
09:40AM	Salesforce initiated, Dollar Tree upgraded: Wall Streets top analyst calls (TipRanks)
May-20-25 07:00AM	PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 (GlobeNewswire)
May-15-25 03:10AM	PolyPid Ltd (PYPD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
May-14-25 07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) +7.01%
Apr-29-25 07:00AM	PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 (GlobeNewswire)
Apr-22-25 07:00AM	PolyPid to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-11-25 07:00AM	PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Mar-03-25 07:00AM	PolyPid to Participate in the 37th Annual ROTH Conference (GlobeNewswire) -8.29%
Feb-13-25 02:09AM	PolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs (GuruFocus.com)
Feb-12-25 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Jan-30-25 07:00AM	PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-29-25 07:00AM	PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025 (GlobeNewswire)
Dec-23-24 07:22PM	PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million (GlobeNewswire) +14.29% -19.29%
Dec-12-24 07:16AM	PolyPid announces research, development collaboration with ImmunoGenesis (TipRanks) -7.53%
Dec-11-24 07:00AM	PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy (GlobeNewswire)
Nov-29-24 01:05PM	PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance (GlobeNewswire)
Nov-14-24 02:08AM	PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-13-24 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 07:00AM	PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference (GlobeNewswire)
Oct-30-24 08:00AM	PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 (GlobeNewswire)
Oct-23-24 07:01PM	Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd (GuruFocus.com) +5.59%
Oct-21-24 07:00AM	PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery (GlobeNewswire) -8.08%
Oct-01-24 07:00AM	PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Sep-03-24 07:00AM	PolyPid to Participate in Three Upcoming Fall Investor Conferences (GlobeNewswire)
Aug-14-24 07:00AM	PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 08:31PM	PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds (GlobeNewswire)
Jul-31-24 07:00AM	PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 (GlobeNewswire)
Jun-18-24 07:00AM	PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial (GlobeNewswire)
Jun-10-24 07:00AM	PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX100 Phase 3 Trial (GlobeNewswire)
May-10-24 05:25PM	PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.39% -8.22%
May-08-24 11:56AM	PYPD Stock Earnings: PolyPid Beats EPS for Q1 2024 (InvestorPlace) -11.32%
07:00AM	PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-01-24 07:00AM	PolyPid to Participate in Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-24 07:00AM	PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX for the Prevention of Abdominal Colorectal Surgical Site Infections (GlobeNewswire)
Apr-24-24 07:00AM	PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024 (GlobeNewswire)
Feb-28-24 07:00AM	PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference (GlobeNewswire) +8.68%
Feb-19-24 12:00PM	PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Feb-15-24 09:41AM	PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-24 07:00AM	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -8.21%
Feb-12-24 07:00AM	PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial (GlobeNewswire)
Jan-31-24 07:00AM	PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024 (GlobeNewswire)
Jan-04-24 04:32PM	PolyPid Announces Private Placement for $16 Million in Gross Proceeds (GlobeNewswire) -5.67% +16.36%
Nov-12-23 10:40AM	PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:00AM	PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)

Show Previous News

PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

CEO & DirectorMs. Dikla Czaczkes Akselbrad

Chief Financial OfficerMr. Jonny Missulawin

Deputy CEO and Executive VP of R&DMs. Dalit Hazan

Chief Operating OfficerMr. Ori Warshavsky

Executive Vice President of OperationsMs. Maria Rubin

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PYPD

Polypid Ltd

Upgrade your Finviz experience